diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5796diaendo-5796Research ArticleСтатьиArticlesГенерик аторвастатина Тулип? в лечении дислипидемии у больных с cахарным диабетом 2 типаGenerik atorvastatina Tulip? v lechenii dislipidemii u bol'nykh s sakharnym diabetom 2 tipaЗалевскаяАлсу ГафуровнаZalevskayaAlsu Gafurovna-ОрловаВ ЛOrlovaV L-ПатракееваЕвгения МихайловнаPatrakeevaEvgenia Mikhailovna-Санкт-Петербургский Государственный медицинский университет им. акад. И.П. Павлова, Санкт-ПетербургГородская многопрофильная больница № 2, Санкт-Петербург200715062007102№2 (2007)4751Copyright © Залевская А.Г., Орлова В.Л., Патракеева Е.М., 20072007Залевская А.Г., Орлова В.Л., Патракеева Е.М.Zalevskaya A.G., Orlova V.L., Patrakeeva E.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5796

Цель. Оценка эффективности и безопасности применения нового генерика аторвастатина ? препарата Тулип (ЛЕК, Словения) у больных СД 2 типа и дислипидемией. Материалы и методы. В открытое проспективное контролируемое исследование эффекта препарата Тулип были включены 20 пациентов. Для сравнения была выбрана группа пациентов (n=20), сопоставимая по демографическим характеристикам, также не получавшая ранее терапию липидснижающими препаратами. Протокол обследования включал стандартный опрос, осмотр, антропометрическое обследование. Лабораторные исследования проводили в сыворотке венозной крови, взятой утром натощак после 12-часового голодания. Для оценки степени компенсации СД определяли уровни холестерина, ЛПНП, ЛПВП, триглицеридов, АЛТ, АСТ в сыворотке (визит 1?3). Уровни HbA1c, холестерина, ЛПНП, ЛПВП, триглицеридов исследовали и в конце наблюдения. Результаты. В основной группе за время наблюдения обнаружено снижение уровня ЛПНП. Увеличение дозы препарата Тулип до 20 мг/день требовалось 9 пациентам. Все больные этой группы отмечали хорошую переносимость препарата. Выводы. Генерик аторвастатина Тулип? Лек, Словения, является эффективным препаратом с высоким уровнем без опасности для лечения дислипидемии у пациентов с СД 2 типа. Улучшение гликемического профиля у больных СД 2 типа не сопровождается спонтанной нормализацией липидного спектра и требует медикаментозной коррекции нарушений липидного обмена.

Тулипдислипидемиясахарный диабет 2 типаReferencesWild S, Roglic G, Green A, Sicree R, King H Global Prevalence of Diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053Wild S, Roglic G, Green A, Sicree R, King H Global Prevalence of Diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053Rosenbloom AL, Joe JR et al. Emerging epidemic of type 2 diabetes in youth. Diabetes Care. 1999 Feb;22(2):345-54Rosenbloom AL, Joe JR et al. Emerging epidemic of type 2 diabetes in youth. Diabetes Care. 1999 Feb;22(2):345-54Rosenbloom AL Increasing incidence of type 2 diabetes in children and adolescents: treatment considerations. Paediatr Drugs. 2002;4:209-21Rosenbloom AL Increasing incidence of type 2 diabetes in children and adolescents: treatment considerations. Paediatr Drugs. 2002;4:209-21Kaufman FR. Type 2 diabetes mellitus in children and youth: a new epidemic. J Pediatr Endocrinol Metab. 2002 May;15 Suppl 2:737-44Kaufman FR. Type 2 diabetes mellitus in children and youth: a new epidemic. J Pediatr Endocrinol Metab. 2002 May;15 Suppl 2:737-44Soltesz G. Diabetes in the young: a paediatric and epidemiological perspective. Diabetologia. 2003 Apr;46(4):447-54Soltesz G. Diabetes in the young: a paediatric and epidemiological perspective. Diabetologia. 2003 Apr;46(4):447-54Kraus H. The St Vincent Declaration: Diabetes Care and Research in Europe. Geneva, WHO, 1992Kraus H. The St Vincent Declaration: Diabetes Care and Research in Europe. Geneva, WHO, 1992Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287: 2570-81Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287: 2570-81Wilson JD ed. Williams Textbook of Endocrinology. 9th ed. Philadelphia WB Saunders; 1998Wilson JD ed. Williams Textbook of Endocrinology. 9th ed. Philadelphia WB Saunders; 1998Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH: Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141:421-431, 2004Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH: Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141:421-431, 2004Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR, for the U.K. Prospective Diabetes Study Group: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: UKPDS 23. BMJ316 : 823-828,1998Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR, for the U.K. Prospective Diabetes Study Group: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: UKPDS 23. BMJ316 : 823-828,1998Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000Holman R. The UKPDS: implications for the dyslipidaemic patient. Acta Diabetol. 2001; 38 Suppl 1:S9-14.Holman R. The UKPDS: implications for the dyslipidaemic patient. Acta Diabetol. 2001; 38 Suppl 1:S9-14.Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabet Care 1993; 16: 434-44.Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabet Care 1993; 16: 434-44.The Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Circualtion 2002; 106: 3143-21.The Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Circualtion 2002; 106: 3143-21.Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239, 2004Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110:227-239, 2004American Diabetes Association: Management of dyslipidemia in adults with diabetes (Position Statement). Diabetes Care 26 (Suppl. 1):S83-S86, 2003American Diabetes Association: Management of dyslipidemia in adults with diabetes (Position Statement). Diabetes Care 26 (Suppl. 1):S83-S86, 2003Dyslipidemia Management in Adults With Diabetes. Diabetes Care 2004; 27: S68-71.Dyslipidemia Management in Adults With Diabetes. Diabetes Care 2004; 27: S68-71.Standards of Medical Care in Diabetes. Diabetes Care 2005; 28: S4-36.Standards of Medical Care in Diabetes. Diabetes Care 2005; 28: S4-36.American Diabetes Association: Standards of medical care in diabetes (Position Statement). Diabetes Care 28 (Suppl. 1):S4 -S36, 2005American Diabetes Association: Standards of medical care in diabetes (Position Statement). Diabetes Care 28 (Suppl. 1):S4 -S36, 2005Reaven GM, ChenY-DI, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 1993;92: 141-6.Reaven GM, ChenY-DI, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 1993;92: 141-6.Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol. 1994 , 5:339-349Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol. 1994 , 5:339-349Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol 1996;7: 167-71Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Curr Opin Lipidol 1996;7: 167-71Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004 Jun;27(6):1496-504Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004 Jun;27(6):1496-504Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 101:975-980, 2000Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP: Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 101:975-980, 2000Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y: Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52:453-462, 2003Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y: Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52:453-462, 2003Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 1998; 82: 3J-10J.Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 1998; 82: 3J-10J.Endo A, Kuroda M, Tsujita Y. ML-236A, ML 236B, ML 236C, new inhibitors of cholesterogenesis produced by Penicillinum citrinum. J Antibiot 1976; 29: 13246-48.Endo A, Kuroda M, Tsujita Y. ML-236A, ML 236B, ML 236C, new inhibitors of cholesterogenesis produced by Penicillinum citrinum. J Antibiot 1976; 29: 13246-48.O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997; 95: 1126-1131O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997; 95: 1126-1131Rosenson R. Non-lipid-lowering effects of statins on atherosclerosis. Curr Cardiol Rep 1999; 1: 225-32.Rosenson R. Non-lipid-lowering effects of statins on atherosclerosis. Curr Cardiol Rep 1999; 1: 225-32.Marchesi S, Lupattelli G, Siepi D, et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol. 2000; 36: 617-621Marchesi S, Lupattelli G, Siepi D, et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol. 2000; 36: 617-621Tan KCB, Chow WS, Tam VHG, et al. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilatation in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2002; 87: 563-568.Tan KCB, Chow WS, Tam VHG, et al. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilatation in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2002; 87: 563-568.Feron O, Dessy C, Desager JP, et al. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 2001; 103: 113-118.Feron O, Dessy C, Desager JP, et al. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation. 2001; 103: 113-118.Romano M, Mezzetti A, Marulli C, et al. Fluvastatin reduces soluble Pselectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Invest Med. 2000; 48: 183-189.Romano M, Mezzetti A, Marulli C, et al. Fluvastatin reduces soluble Pselectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. J Invest Med. 2000; 48: 183-189.Aviram M, Hussein O, Rosenblat M, et al. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol. 1998; 31: 39-45.Aviram M, Hussein O, Rosenblat M, et al. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. J Cardiovasc Pharmacol. 1998; 31: 39-45.Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001; 103: 1933-1935Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001; 103: 1933-1935Joukhadar C, Klein N, Prinz M, et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost. 2001; 85: 47-51.Joukhadar C, Klein N, Prinz M, et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost. 2001; 85: 47-51.Wiklund O, Mattsson-Hult n L, Hurt-Camejo E, et al. Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med. 2002; 251: 338-347Wiklund O, Mattsson-Hult n L, Hurt-Camejo E, et al. Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med. 2002; 251: 338-347Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004;57: 640-51Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004;57: 640-51Grundy SM, Howard B, Smith SJr et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002; 105: 2231-9.Grundy SM, Howard B, Smith SJr et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation 2002; 105: 2231-9.Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian simvastatin survival study (4S). Diabetes Care 1997;20: 614-20.Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian simvastatin survival study (4S). Diabetes Care 1997;20: 614-20.Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian simvastatin survival study. Arch Intern Med 1999;159: 2661-7.Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian simvastatin survival study. Arch Intern Med 1999;159: 2661-7.Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344: 1383-9Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344: 1383-9Collins R, Armitage J, Parish S et al. The Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.Collins R, Armitage J, Parish S et al. The Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.Colhoun HM, Betteridge DJ, Durrington PN et al. The CARDS Investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.Colhoun HM, Betteridge DJ, Durrington PN et al. The CARDS Investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.Gaede P., Vedel P. Et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. : N Engl J Med. 2003 Jan 30; 348(5):383-93.Gaede P., Vedel P. Et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. : N Engl J Med. 2003 Jan 30; 348(5):383-93.

The authors declare that there are no conflicts of interest present.